All articles by Abigail Beaney

Abigail Beaney

Abigail Beaney is the editor of Clinical Trials Arena. Abigail has expertise in clinical trial regulation, trial design, outsourcing, and cell and gene therapies. Abigail also has covered news and has a wealth of knowledge across several therapy areas including neurodegenerative, infectious and metabolic diseases. Abigail holds a first-class BA (Hons) degree in Journalism from the University of Central Lancashire in the United Kingdom. She has also obtained the National Qualification in Journalism through the UK's media industry body, the National Council for the Training of Journalists. Contact Abigail

Pharma positions itself for 2026 amid an evolving US landscape

After President Donald Trump’s administration took office in early 2025, a series of policy changes have directly impacted the pharma…
Ipsen’s ultra-rare bone disease drug flops in Phase II trial

Ipsen’s fidrisertib has failed to show meaningful benefit above placebo in a Phase II trial in patients with fibrodysplasia ossificans…
Takeda to seek approval of plaque psoriasis pill on Phase III trial data

Takeda’s once-daily oral plaque psoriasis (PsO) drug has met all its endpoints in two pivotal trials, with the company set…
Galderma’s Nemluvio shows itch reduction in 48 hours

Galderma’s dermatology monoclonal antibody (mAb) Nemluvio (nemolizumab) has shown proof of improving symptoms of atopic dermatitis (AD) and prurigo nodularis…
DBV to make new approval bid for VIASKIN Peanut on Phase III trial

DBV Technologies will be making another attempt at gaining US Food and Drug Administration (FDA) approval for its peanut allergy…

Aviceda Therapeutics to advance eye disease drug despite Phase IIb loss

Aviceda Therapeutics’ eye disease drug will advance to Phase III, despite it failing to meet the primary endpoint in a…
Gilead’s HIV ART combo deemed non-inferior in second Phase III trial

Gilead Sciences’ human immunodeficiency virus (HIV) single-tablet combination antiretroviral therapy (ART) has proven non-inferior to standard of care (SoC) in a…
Rezolute stock crashes after sole pipeline candidate fails Phase III

Rezolute’s stock has crashed after its only pipeline product flopped in a Phase III trial. In the sunRIZE trial (NCT06208215),…
Lilly’s triple G agonist boasts 28.7% weight loss in Phase III trial

Eli Lilly’s triple glucagon agonist has achieved up to 28.7% weight loss in a Phase III trial. In the TRIUMPH-4…
AI takes charge of data, but challenges linger

For years, one of the biggest barriers to effectively implementing artificial intelligence (AI) into clinical trial data management has been…